Author
Listed:
- Ting Zhang
(Thoracic Disease Research Unit, Cancer Center and College of Medicine, Mayo Clinic, 200 First Street SW, Stabile Building Room st8-08 Rochester, Minnesota 55905, USA
Cancer Center and College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA)
- Lixia Guo
(Thoracic Disease Research Unit, Cancer Center and College of Medicine, Mayo Clinic, 200 First Street SW, Stabile Building Room st8-08 Rochester, Minnesota 55905, USA
Cancer Center and College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA)
- Chad J. Creighton
(Dan Duncan Cancer Center, Baylor College of Medicine)
- Qiang Lu
(Mayo Clinic College of Medicine)
- Don L. Gibbons
(M.D. Anderson Cancer Center
M.D. Anderson Cancer Center)
- Eunhee S. Yi
(Mayo Clinic)
- Bo Deng
(Mayo Clinic College of Medicine
Institute of Surgery Research, Daping Hospital, Third Military Medical University)
- Julian R. Molina
(Mayo Clinic)
- Zhifu Sun
(Mayo Clinic)
- Ping Yang
(Mayo Clinic College of Medicine)
- Yanan Yang
(Thoracic Disease Research Unit, Cancer Center and College of Medicine, Mayo Clinic, 200 First Street SW, Stabile Building Room st8-08 Rochester, Minnesota 55905, USA
Cancer Center and College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA)
Abstract
The Zinc-finger E-box-binding Homeobox-1 (ZEB1) is a transcription factor that promotes epithelial–mesenchymal transition (EMT) and acts as an oncogene in KRAS-mutated lung cancer models. Here we report that ZEB1 exerts the opposite effect in EGFR-mutated lung cancer cells, where it suppresses growth by increasing microRNA-200 targets to antagonize ERBB3, a driver of mutant EGFR-dependent cell growth. Among these targets, NOTCH1 represses ERBB3 promoter activity and the expression of ERBB3. Furthermore, we find that EGFR inhibitor treatment, which inhibits the growth of EGFR-mutated cells, induces ZEB1. Despite its growth-inhibiting effect, EGFR inhibitor-induced ZEB1 strongly promotes EMT-dependent resistance to EGFR inhibitors partially through NOTCH1, suggesting a multifunctional role for NOTCH1 in EGFR-mutated cells. These results support a previously unrecognized genetic cell context-dependent role for ZEB1 and suggest that NOTCH1 may be a useful target for treating resistance to EGFR inhibitors, especially EMT-driven resistance.
Suggested Citation
Ting Zhang & Lixia Guo & Chad J. Creighton & Qiang Lu & Don L. Gibbons & Eunhee S. Yi & Bo Deng & Julian R. Molina & Zhifu Sun & Ping Yang & Yanan Yang, 2016.
"A genetic cell context-dependent role for ZEB1 in lung cancer,"
Nature Communications, Nature, vol. 7(1), pages 1-13, November.
Handle:
RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms12231
DOI: 10.1038/ncomms12231
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms12231. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.